Tacrolimus Does Not Abrogate the Increased Risk of Acute Graft-Versus-Host Disease after Unrelated-Donor Marrow Transplantation with Allelic Mismatching at HLA-DRB1 and HLA-DQB1

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 2 A, 2000, Pages 190-197

  Przepiorka, Donna ^a,b   Saliba, Rima ^b   Cleary, Karen ^b   Fischer, Harald ^b   Tonai, Richard ^c   Fritsche, Herbert ^b   Khouri, Issa F ^b   Folloder, Jody ^b   Ueno, Naoto T ^b   Mehra, Rakesh ^b   Ippoliti, Cindy ^b   Giralt, Sergio ^b   Gajewski, James ^b   Donato, Michele ^b   Claxton, David ^b   Braunschweig, Ira ^b   Van Besien, Koen ^b   Anderlini, Paolo ^b   Andersson, Borje S ^b   Champlin, Richard ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HLA DQB1; HLA DRB1; Tacrolimus; Unrelated donor marrow transplantation

Indexed keywords

HLA DQ ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLELE; ARTICLE; BLOOD; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; COMPARATIVE STUDY; DONOR; DRUG EFFECT; FEMALE; GENE; GENETICS; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; MALE; MIDDLE AGED; MORTALITY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLELES; BONE MARROW TRANSPLANTATION; FEMALE; FILGRASTIM; GENES, MHC CLASS II; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; TACROLIMUS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 0033658448     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70042-5     Document Type: Article

References (44)

1. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
2. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood. 1993;81:249-253.
3. Davies SM, Shu XO, Blazar BR, et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood. 1995;86:1636-1642.
4. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767-1777.
5. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DRB1 identical unrelated donor marrow transplantation. Blood. 1995;86:1606-1613.
6. Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQB1 as a transplantation antigen. Proc Natl Acad Sci U S A. 1996;93:15358-15363.
7. Speiser DE, Tiercy J-M, Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood. 1996;87:4455-4462.
8. Gajewski J, Gjertson D, Cecka M, et al. The impact of T-cell depletion on the effects of HLA DRB1 and DQB1 allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3:76-82.
9. Baxter-Lowe LA, Kollman C, Awdeh Z, et al. Use of molecular HLA analysis to examine the relationship between class II HLA disparity and outcome of unrelated bone marrow transplants [abstract]. Blood.1997;90(suppl 1):397a.
10. Thornley I, Rolland-Grinton M, Forst G, et al. Molecular HLA-C and DQBI typing, outcome after pediatric matched unrelated donor bone marrow transplantation [abstract]. Blood. 1998;92(suppl 1):141a.
11. Devergie A, Apperley JF, Labopin M, et al. for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation: European results of matched unrelated donor bone marrow transplantation for chronic myelogenous leukemia: impact of HLA class II matching. Bone Marrow Transplant. 20:1997;11-19.
12. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:1980.
13. Kino T, Hatanaka H, Hashimoto M, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiotics. 1987;40:1249-1255.
14. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiotics. 1987;40:1256-1265.
15. Storb R, Raff RF, Appelbaum FR, et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation. 1993;56:800-807.
16. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996;88:4383-4389.
17. Nash RA, Piñeiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996;88:3634-3641.
18. Geller RB, Devine SM, O'Toole K, et al. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation. Bone Marrow Transplant. 1997;20:219-225.
19. Nash RA, Antin J, Karanes C, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine (CSP) for prophylaxis of acute graft-versus-host disease (GVHD) after marrow transplantation from matched unrelated donors [abstract]. Blood. 1997; 90(suppl 1):561a.
20. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minimethotrexate vs T-cell depletion, cyclosporine and immunotoxin for prevention of acute graft-vs-host disease (GVHD) after HLA-nonidentical marrow transplantation [abstract]. Blood. 1995; 86(suppl 1):621a.
21. Park MS, Tonai R. Phenotype frequencies of the class II DNA alleles by the patterns of sequence specific primer mixtures: population studies and probable haplotypes. In: Terasaki PI, Cecka JM, eds. Clinical Transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory; 1992:475-500.
22. Bodmer JG, Marsh SGE, Albert ED. Nomenclature for factors of the HLA system, 1991. Tissue Antigens. 1993;39:161.
23. Przepiorka D, Khouri I, Ippoliti C, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-vs-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999;24:763-768.
24. Przepiorka D, Devine SM, Fay JW, Uberti JP, Wingard JR. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant. 1999;24:1053-1056.
25. Snover DC. Biopsy interpretation in bone marrow transplantation. In: PP Rosen, RE Fechner, eds. Pathology Annual, Part 2. Hartford, CT: Appleton & Lange, 1989:63-101.
26. Przepiorka D, Weisdorf D, Martin P, et al. Report of the 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
27. Sobocinski KA, Horowitz MM, Rowlings PA, et al. Bone marrow transplantation-1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother. 1994;3:95-102.
28. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1588.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
30. Khouri IF, Ippoliti C, Gajewski J, Przepiorka D, Champlin RE. Neutropenia following allogeneic bone marrow transplantation: response to therapy with high dose intravenous immunoglobulin. Am J Hematol. 1996;52:313-315.
31. Fay JW, Nash RA, Wingard JR, et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. Transplant Proc. 1995;27:1374.
32. Przepiorka D, Nash RA, Wingard JR, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant. 1999;5:94-97.
33. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.
34. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactiviry during allograft rejection in mice. J Immunol. 1999;162:352-358.
35. van Els CA, Zantvoort E, Jacobs N, et al. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules. Bone Marrow Transplant. 1990;5:365-372.
36. Petersdorf EW, Smith AG, Mickelson EM. et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood. 1993;81:1923-1932.
37. Santamaria P, Reinsmoen NL, Lindstrom AL, et al. Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. Blood. 1994;83:3834.
38. Prasad V, Kernan NA, Heller G, O'Reilly RJ, Yang SY. HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci. Biol Blood Marrow Transplant. 1999;5:77-85.
39. Scott I, O'Shea J, Bunce M, et al. Molecular typing shows a high level of HLA class I incompatibility in serologically well-matched donor/patient pairs: implications for unrelated bone marrow donor selection. Blood. 1998;92:4864-4871.
40. Grundschober C, Rufer N, Sanchez-Mazas A, et al. Molecular characterization of HLA-C incompatibilities in HLA-ABDR-matched unrelated bone marrow donor-recipient pairs. Sequence of two new Cw alleles (Cw*02023 and Cw*0707) and recognition by cytotoxic T lymphocytes. Tissue Antigens. 1997;49:612-623.
41. Prasad VK, Kernan NA, Heller G, et al. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood. 1999;93:399-409.
42. Nagler A, Brautbar C, Slavin S, Bishara A. Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity. Bone Marrow Transplant. 1996;18:891-897.
43. Sasazuki T, Juji T, Morishima Y, et al. for the Japan Marrow Donor Program: Effect of matching class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177-1185.
44. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226-4235.